Teva revises planned US submission date for new Copaxone dosing regimen
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has pushed back its timelines for a US submission for its new three-times-weekly dosing regimen for Copaxone (glatiramer acetate injection), the company revealed, ahead of presenting detailed positive Phase III data for the blockbuster multiple sclerosis drug.